Panel Backs Limited New Olaparib Use in Prostate Cancer : vi

An expert panel recommended restricting the expanded first-line indication to patients whose metastatic castration-resistant prostate tumors have BRCA mutations.

Related Keywords

Jorgej Nieva , Terrencem Kungel , Los Angeles , Ravia Madan , Susan Galbraith , Cancer Research , National Cancer Institute , Drug Administration , Oncologic Drugs Advisory Committee , University Of Southern California , Astrazeneca , Southern California , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Prostate , Breast Cancer , Alignant Breast Neoplasm , Ovarian Cancer , Alignant Ovarian Neoplasm , Cancer , Alignant Neoplasia , Arcinoma , Prostatic , Brca , Malignant Pancreatic Neoplasm , Pancreatic Cancer , Ancer Pancreatic , Toxicology , Genomics , Genomic Medicine , Edicine Genomic , Tumor , Biomarker , Iological Marker , Blood Transfusi ,